During the quarter, ZymIQ carried out strategic recruitment to add important expertise in sales/marketing and Biopharma. These reinforcements are part of building an organization equipped for 2026. At the same time, product development is progressing and a review of the production chain has been initiated to enable future large-scale.

1 jan – 31 dec 2025

• Net sales increased by 48% to SEK 1,902 thousand (1,281)
• Loss after tax amounted to SEK -12,167 thousand (-10,954)
• Earnings per share amounted to SEK -1.39 (–1.04)
• Cash and cash equivalents amounted to SEK 2,488 thousand (3,189)

1 okt – 31 dec 2025

• Net sales amounted to SEK 356 thousand (269)
• Loss after tax amounted to SEK -5,925 thousand (-2,610)
• Earnings per share amounted to SEK -0.67 (–0.31)

Significant events during the reporting period

• ZymIQ receives a positive response from the European Patent Office.
• Emil Bacos has been recruited as Chief Commercial Officer (CCO) of ZymIQ Technology AB starting December 8th.
• ZymIQ has presented its enzyme technology to potential investors at the BioStock Life Science Summit, Lund.
• New agreement between ZymIQ and fjör.
• New cosmetics products have been developed for the Asian market.

Significant events after the reporting period

• Karin Bryder has been recruited as Chief Operating Officer (COO) of the subsidiary ZymIQ Biopharma AB.
• An issue of approximately 519,000 shares was registered with the Swedish Companies Registration Office in January 2026.